文献速递头颈外科

口咽鳞状细胞癌经口机器人手术后30天再入院率的全国趋势

National Trends in 30-Day Readmission Following Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

该回顾性人群队列研究利用2010至2017年全国再入院数据库,纳入接受经口机器人手术治疗口咽鳞状细胞癌的患者,分析30天再入院的风险因素。加权共5544例患者,总体再入院率为17.5%(n=971),且研究期间再入院率从2010年的23.7%(50/211)降至2017年的9.1%(58/633)。男性(AOR 1.54;95% CI 1.07-2.20)和充血性心力衰竭(AOR 2.42;95% CI 1.28-4.58)与再入院风险升高相关,同期行选择性颈清扫(AOR 0.30;95% CI 0.22-0.41)与再入院率降低相关。

要点

  • 接受经口机器人手术治疗口咽鳞状细胞癌的患者30天再入院率为17.5%,研究期间呈下降趋势。
  • 男性(AOR 1.54)和充血性心力衰竭(AOR 2.42)与再入院风险升高相关。
  • 同期行选择性颈清扫(AOR 0.30)与再入院率降低相关。

核心结论

  • 接受经口机器人手术治疗口咽癌的患者再入院率随时间下降,但部分患者仍需再入院,最常见原因为出血、感染和电解质紊乱。
  • 同期颈清扫可能对再入院具有保护作用。
  • 明确经口机器人手术治疗口咽鳞状细胞癌后再入院的风险因素,为循证共享决策、质量改进举措和改善患者咨询提供了机会。

研究设计与样本

  • 回顾性、基于人群的队列研究
  • 数据来源为2010至2017年全国再入院数据库
  • 通过国际疾病分类编码识别所有接受经口机器人手术治疗口咽鳞状细胞癌的患者
  • 排除标准为年龄小于18岁或索引入院或再入院信息不完整
  • 分析于2023年4月至10月进行

主要发现

  • 总体30天再入院率为17.5%(n=971)。
  • 再入院率从2010年的23.7%(50/211例)降至2017年的9.1%(58/633例)。
  • 男性与再入院风险升高相关(AOR 1.54;95% CI 1.07-2.20)。
  • 充血性心力衰竭与再入院风险升高相关(AOR 2.42;95% CI 1.28-4.58)。
  • 同期行选择性颈清扫与再入院率降低相关(AOR 0.30;95% CI 0.22-0.41)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: As the incidence of oropharyngeal squamous cell carcinoma (OPSCC) continues to rise in the US, an increasing number of patients are being treated with transoral robotic surgery (TORS). Readmission following surgery can potentially delay initiation of adjuvant treatment and affect survival outcomes. OBJECTIVE: To identify risk factors for 30-day postoperative readmission in patients undergoing TORS for OPSCC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based cohort study used data from the Nationwide Readmissions Database from 2010 to 2017. All patients undergoing TORS for OPSCC were identified using International Classification of Diseases codes and included. Exclusion criteria were age younger than 18 years or incomplete information regarding index admission or readmission. The analysis was performed from April to October 2023. EXPOSURE: TORS for OPSCC. MAIN OUTCOMES AND MEASURES: Univariate and multivariate analyses were performed to determine factors associated with 30-day readmission. Covariates included demographics and medical comorbidities, socioeconomic factors, hospital characteristics, and surgical details. Trends in readmission over time, reasons for readmission, and characteristics of the readmission were also examined. RESULTS: A weighted total of 5544 patients (mean [SD] age, 60.7 [0.25] years; 4475 [80.7%] male) underwent TORS for OPSCC. The overall readmission rate was 17.5% (n = 971), and these rates decreased over the study period (50 of 211 patients [23.7%] in 2010 vs 58 of 633 patients [9.1%] in 2017). Risk factors associated with readmission included male sex (adjusted odds ratio [AOR], 1.54; 95% CI, 1.07-2.20) and a diagnosis of congestive heart failure (AOR, 2.42; 95% CI, 1.28-4.58). Factors associated with decreased rate of readmission included undergoing concurrent selective neck dissection (AOR, 0.30; 95% CI, 0.22-0.41). Among the 971 readmissions, the most common readmission diagnoses were bleeding (151 [15.6%]), electrolyte and digestive problems (44 [4.5%]), pneumonia (44 [4.5%]), and sepsis (26 [2.7%]). CONCLUSIONS AND RELEVANCE: In this cohort study, readmission rates following TORS for oropharynx cancer decreased over time; however, a subset of patients required readmission most commonly related to bleeding, infection, and electrolyte imbalance. Concurrent neck dissection may be protective against readmission. Elucidation of risk factors for readmission after TORS for OPSCC offers opportunities for evidence-based shared decision-making, quality improvement initiatives, and improved patient counseling.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Nyirjesy SC, McCrary HC, Zhao S, et al. National Trends in 30-Day Readmission Following Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38153724. doi:10.1001/jamaoto.2023.4025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。